People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cydan II, Inc. | — | Biotechnology | Series A | $10.7M | $385.6M | 2017 |
| Cydan, LLC | — | Pharmaceuticals | Series A | $10.6M | $204.5M | 2013 |
James M. McArthur at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James M. McArthur on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christoph M. Adams | 2 | 4 |
| David Mott | 1 | 9 |
| Mette Kirstine Agger | 1 | 6 |
| Sara Nayeem | 1 | 4 |
| David M. Mott | 1 | 4 |
| Barbara Dalton | 1 | 2 |
| Cristina Csimma | 1 | 2 |
| Sara M. Nayeem | 1 | 2 |
| Sandip Kirstine Agarwala | 1 | 2 |
| Barbara M. Dalton | 1 | 1 |
| Deborah M. Geraghty | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.